Trial Profile
Safety and efficacy of exenatide once weekly injection versus metformin, dipeptidyl peptidase-4 inhibitor, or thiazolidinedione as monotherapy in drug-naive patients with type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Metformin; Pioglitazone; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DURATION-4
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 05 Oct 2018 Results assessing the efficacy and safety of exenatide once weekly across 10 comparator-controlled studies from the DURATION clinical programme (n=2251) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
- 30 Dec 2011 Results published in Diabetes Care.